Pfizer, GSK to benefit as CDC panel endorses wider use of RSV shots

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to expand the use of vaccines against the respiratory syncytial virus (RSV) for a broader population in the U.S.

The